返回 
加入收藏
扶正类中成药临床使用风险及监护要点分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 扶正类中成药临床使用风险及监护要点分析 |
| TITLE： | Clinical risk and monitoring essentials of tonifying Chinese patent medicine |
| 摘要： | 目的 探究扶正类中成药的临床使用风险及监护要点。方法统计2024年版《国家基本药物目录》中所列的扶正类中成药品种，并使用“丁香园”等软件收集说明书，按照“药物名称“”成分“”禁忌“”注意事项“”药物相互作用”等进行分类和整理，依据2020年版《中国药典》等相关标准规范中药饮片的名称，通过查阅文献资料整理特殊人群禁忌的中药饮片、扶正类中成药及相关临床应用等方面的信息，依靠院内信息系统最终建立扶正类中成药数据库，以此来深入探究扶正类中成药的临床使用风险及监护要点。结果共纳入222种扶正类中成药，其中肝肾功能异常者禁用/慎用91种（占比40.99%），高血压患者禁用/慎用9种（占比4.05%），儿童禁用/慎用8种（占比3.60%），运动员禁用/慎用109种（占比49.10%）。结论扶正类中成药适用于虚证，存在一定的临床使用风险；肝肾功能不全等易高发不良反应的人群，用药时需特别注意。 |
| ABSTRACT： | OBJECTIVE To explore the clinical risks and monitoring essentials associated with tonifying Chinese patent medicine. METHODS The varieties of tonifying Chinese patent medicines listed in the National Basic Drug List （2024 edition） were counted. Package inserts were collected using software such as “Dingxiangyuan” and then classified and organized according to criteria such as “drug name”“ingredients”“contraindications”“precautions”“drug interactions”. The names of traditional Chinese medicine （TCM） decoction pieces were standardized in accordance with the Chinese Pharmacopoeia （2020 edition） and other relevant standards； literature was reviewed to compile information on TCM decoction pieces that required caution/were contraindicated in special populations， as well as tonifying Chinese patent medicines and their related clinical applications. Then， a database for tonifying Chinese patent medicines was ultimately established by relying on the hospital’s internal information system， so as to conduct an in-depth exploration of the clinical usage risks and key monitoring points of tonifying Chinese patent medicines. RESULTS A total of 222 tonifying traditional Chinese medicines were evaluated. Contraindications or requirements for cautious use were identified in 91 （40.99%） for hepatic or renal impairment， 9 （4.05%） for hypertension， and 8 （3.60%） for pediatric patients， and 109 （49.10%） were designated as contraindicated or requiring caution for athletes. CONCLUSIONS Although tonifying Chinese patent medicines are indicated for deficiency patterns， their use is accompanied by measurable clinical risk， especially in individuals with hepatic or renal compromise who are prone to adverse reactions. |
| 期刊： | 2025年第36卷第23期 |
| 作者： | 孙欢；翟巧利；徐婕；楼冰；公丕君；辛蓓玮 |
| AUTHORS： | SUN Huan，ZHAI Qiaoli，XU Jie，LOU Bing，GONG Pijun，XIN Beiwei |
| 关键字： | 扶正类中成药；使用风险；药学监护；安全用药；特殊人群 |
| KEYWORDS： | tonifying traditional Chinese medicine； clinical risk； pharmaceutical care； safe use of drugs； special populations |
| 阅读数： | 5 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
